<DOC>
	<DOCNO>NCT00038181</DOCNO>
	<brief_summary>The goal clinical research study find whether safe treat patient diagnose locally advanced prostate cancer drug Thalidomide remove tumor ( radical retropubic prostatectomy ) . Researchers also want learn Thalidomide shrink slow growth prostate cancer surgery</brief_summary>
	<brief_title>Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer</brief_title>
	<detailed_description>1 . To determine efficacy ( rate tumor reduction PSA decline ) pre-operative treatment thalidomide patient locally advanced prostate carcinoma . 2 . To determine safety toxicity ( excessive bleeding , wound heal problem ) preoperative therapy thalidomide patient locally advanced prostate carcinoma undergo RRP . 3 . To obtain qualitative measurement thalidomide 's effect vivo : 1. endothelial cell / neo-vascularity /angiogenic growth factor : - Assessment neovascularity ( MVD ) - Dual fluorescent label technique evaluate apoptosis CD-31 positive cell ( TUNEL ) - bFGF , VEGF , EGF TGF expression PCa epithelium prostatic stroma - Modulation endothelial marker ( serum : E-selectin Thrombomodulin ) - Modulation serum VEGF urine bFGF level , Changes tumor blood flow 2. epithelial compartment : - Apoptosis prostate cancer cell ( TUNEL ) - Proliferation ( PCNA ) 3. quality life</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criteria Prostatic adenocarcinoma without evidence regional distant metastasis , clinical stage T1cT2c Gleason score &gt; 7 initial biopsy PSA &gt; 10 ng/dl clinical stage T3 . Negative bone scan CT abd/pelvis . Life expectancy least 10 year . Surgical candidate radical prostatectomy ECOG performance status &lt; 2 . Patients must concurrent malignancy ( within past 5 year , exception nonmelanoma skin cancer treat superficial transitional cell carcinoma bladder ) . Peripheral granulocyte count &gt; 1,500/mm3 , platelet count &gt; 100,000/mm3 Hb &gt; 10.0 gm/dl , adequate hepatic function bilirubin &lt; 1.5 mg % SGPT &lt; 2.5x upper limit normal , adequate renal function define serum creatinine &lt; 1.5 mg % creatinine clearance &gt; 40 ml/min . Patients biochemical hypothyroidism thyroid hormone replace concurrent start study . Patients clinical hypothyroidism thyroid replace prior start study . Informed consent indicate patient aware investigational nature study , keep policy institution . The approved consent form append protocol . Patients must willing able travel UTMDACC reevaluation necessary per protocol . Patients counsel possibility thalidomide may present semen must use latex condom every time sexual intercourse woman therapy 4 week discontinue thalidomide , even successful vasectomy . Exclusion criterion Patients receive prior hormonal , immuno , radiation chemotherapy prostate carcinoma exclude trial . Prior herbal and/or homeopathic medication allow discontinue least 2 week prior study entry . PCSPES consider hormonal therapy . Patients history substantial noniatrogenic bleeding diathesis patient macroscopic hematuria active GI bleeding eligible . Patients uncontrolled cardiac , respiratory , hepatic , renal , neurologic psychiatric disorder exclude trial . Patients NCI grade 2 great peripheral neuropathy cause ( clinically detectable ) , receive anticonvulsive medication eligible trial . Patients receive sedative/hypnotic agent discontinue ( necessary ) eligible study . Patients positive HIV exclude trial .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>